Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus
- 2 November 2016
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 47 (10), 1072-1078
- https://doi.org/10.1111/hepr.12834
Abstract
Aim No pharmacological therapies have been established for non‐alcoholic fatty liver disease (NAFLD). Sodium glucose cotransporter 2 inhibitor (SGLT2I) was developed for the treatment of adults with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy of SGLT2I in NAFLD patients with T2DM. Methods Twenty‐four biopsy‐proven NAFLD patients with T2DM who received SGLT2I for 24 weeks were retrospectively enrolled as the SGLT2I group. Another 21 NAFLD patients with T2DM treated with dipeptidyl peptidase‐4 inhibitor (DPP4I) for 24 weeks were selected as the DPP4I group. Clinical data were evaluated at baseline and at 4, 12, and 24 weeks. Seventeen patients in the SGLT2I group were evaluated by body composition before and after therapy. Results Not only body weight and hemoglobin A1c but also transaminase activities were significantly decreased in the SGLT2I group. Reductions in transaminase activities were similar between SGLT2I and DPP4I groups. In the SGLT2I group, body mass index and fasting plasma glucose also decreased after the treatment. Conclusion Sodium glucose cotransporter 2 inhibitor can be a novel promising agent for the treatment for NAFLD patients with T2DM. Prospective randomized controlled trials are warranted to confirm this efficacy of SGLT2I on NAFLD with T2DM.Keywords
This publication has 16 references indexed in Scilit:
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in MicePLOS ONE, 2016
- Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitusDiabetology & Metabolic Syndrome, 2015
- The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndromeMetabolism, 2015
- Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male MiceJournal of Clinical and Experimental Hepatology, 2015
- The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trialHepatology, 2014
- Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes MellitusHepato-Gastroenterology, 2011
- Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitisHepatology, 2009
- Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2008
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitisHepatology, 2004
- Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological LesionsAmerican Journal Of Gastroenterology, 1999